20 completed, 2 terminated, 1 unknown. 16 Phase 1, 8 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 14, Terminated 2 |
| Phase 2 | 8 | Completed 6, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Vion Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine Laromustine (VNP40101M) and Ara-C - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 1 / Phase 2 | Terminated | Viron Therapeutics Inc | 25 | 2008-03-01 | 2019-01-28 |
| VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma CLORETAZINE, temozolomide - Brain and Central Nervous System Tumors | Phase 1 | Terminated | Northwestern University | 14 | 2007-08-01 | 2011-08-26 |
| Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies Cloretazine, Fludarabine - Hematologic Malignancies | Phase 1 | Completed | M.D. Anderson Cancer Center | 5 | 2007-08-01 | 2012-07-31 |
| VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia cytarabine, laromustine - Leukemia | Phase 2 | Unknown | Vion Pharmaceuticals | 85 | 2006-05-01 | 2014-01-10 |
| VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia hydroxyurea, laromustine - Leukemia, Myelodysplastic Syndromes | Phase 2 | Completed | Vion Pharmaceuticals | 230 | 2005-11-01 | 2013-07-18 |
| VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer laromustine - Lung Cancer | Phase 2 | Completed | Vion Pharmaceuticals | 87 | 2005-09-01 | 2013-11-06 |
| VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders laromustine - Leukemia, Lymphoma | Phase 1 / Phase 2 | Completed | Vion Pharmaceuticals | 35 | 2005-07-01 | 2013-07-18 |
| Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia cytarabine, laromustine, placebo - Leukemia | Phase 3 | Completed | Vion Pharmaceuticals | 420 | 2005-03-01 | 2013-11-06 |
| Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias laromustine, temozolomide - Leukemia | Phase 1 | Completed | Vion Pharmaceuticals | 25 | 2004-09-01 | 2013-07-18 |
| VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies cytarabine, laromustine - Leukemia, Myelodysplastic Syndromes | Phase 1 | Completed | Vion Pharmaceuticals | 2003-06-01 | 2013-07-18 | |
| 3-AP and Cytarabine in Treating Patients With Hematologic Cancer cytarabine, triapine - Leukemia, Myelodysplastic Syndromes | Phase 1 | Completed | Vion Pharmaceuticals | 2003-03-01 | 2013-07-18 | |
| 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer gemcitabine hydrochloride, triapine - Pancreatic Cancer | Phase 2 | Completed | Vion Pharmaceuticals | 2003-01-01 | 2013-08-02 | |
| 3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer gemcitabine hydrochloride, triapine - Lung Cancer | Phase 2 | Completed | Vion Pharmaceuticals | 2003-01-01 | 2013-11-06 | |
| 3-AP in Treating Patients With Advanced Prostate Cancer triapine - Prostate Cancer | Phase 2 | Completed | Vion Pharmaceuticals | 2002-12-01 | 2013-11-06 | |
| VNP40101M in Treating Patients With Advanced or Metastatic Cancer laromustine - Lymphoma, Small Intestine Cancer | Phase 1 | Completed | Vion Pharmaceuticals | 2002-10-01 | 2013-07-18 | |
| VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome laromustine - Leukemia, Myelodysplastic Syndromes | Phase 1 | Completed | Vion Pharmaceuticals | 2002-04-01 | 2013-07-18 | |
| Combination Chemotherapy in Treating Patients With Advanced Cancer cisplatin, triapine - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Vion Pharmaceuticals | 2001-03-01 | 2013-07-18 | |
| VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas laromustine - Lymphoma, Small Intestine Cancer | Phase 1 | Completed | Vion Pharmaceuticals | 2001-03-01 | 2013-07-18 | |
| 3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer cisplatin, paclitaxel, triapine - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Vion Pharmaceuticals | 2000-12-01 | 2013-07-18 | |
| VNP20009 in Treating Patients With Advanced Solid Tumors salmonella VNP20009 - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Vion Pharmaceuticals | 2000-05-01 | 2013-07-18 |
Showing 20 of 23. Sign in to see all of them.
Leukemia (10) · Leukemia, Myeloid, Acute (8) · Congenital Abnormalities (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Myelodysplastic Syndromes (5) · Hodgkin Disease (4) · Leukemia, Myelomonocytic, Chronic (4) · Lymphoma (4) · Anemia, Refractory, with Excess of Blasts (3) · Blast Crisis (3) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (3) · Lymphoma, Large B-Cell, Diffuse (3) · Myelodysplastic-Myeloproliferative Diseases (3) · Myeloproliferative Disorders (3)
laromustine (13) · 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (8) · Cytarabine (5) · Cisplatin (2) · Gemcitabine (2) · Temozolomide (2) · VNP 20009 (2) · Cefixime (1) · Ceftriaxone (1) · Ciprofloxacin (1) · Hydroxyurea (1) · Paclitaxel (1) · Trimethoprim, Sulfamethoxazole Drug Combination (1) · fludarabine (1) · fludarabine phosphate (1)
United States (23) · United Kingdom (4) · France (3) · Belgium (2) · Netherlands (2) · Canada (1) · Germany (1) · Greece (1) · Poland (1) · Serbia (1)
Mario Sznol, MD (14) · Bonny L. Johnson, RN, MSN (5) · Francis J. Giles, MD (1) · Jeffrey Raizer, MD (1) · Roy B. Jones, MD, PhD (1)
PMID 16278404, PMID 17146105, PMID 19710500, PMID 20511167, PMID 27878356